Eli Lilly and Company (NYSE:LLY) Trading Down 2.1% – Here’s Why

Eli Lilly and Company (NYSE:LLY) dropped 2.1% during mid-day trading on Thursday . The company traded as low as $965.60 and last traded at $982.85. Approximately 3,760,008 shares traded hands during trading, an increase of 14% from the average daily volume of 3,306,408 shares. The stock had previously closed at $1,003.57.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched “Lilly Employer Connect,” a direct-to-employer platform designed to broaden employer coverage of obesity drugs (including Zepbound/tirzepatide), with flexible benefit designs and a $449 single‑patient KwikPen option to lower out-of-pocket costs and speed adoption. This can increase uptake and reduce payer friction for high-margin obesity medicines. PR Newswire: Employer Connect launch
• Positive Sentiment: Multiple outlets report Lilly is actively pitching employers to cover GLP‑1/dual‑agonist obesity treatments — a distribution push that could materially expand the patient base and underpin continued sales growth for Mounjaro/Zepbound. CNBC: Employer coverage program
• Positive Sentiment: Pipeline progress: Lilly completed/updated the TRANSCEND‑T2D‑1 retatrutide Phase 3 program and advanced an abemaciclib combination in prostate cancer (early‑stage data), both reinforcing long‑term growth levers beyond weight‑loss drugs. Positive trial news supports upside to future revenue and de‑risking of promising assets. TipRanks: TRANSCEND‑T2D‑1 update
• Positive Sentiment: Regulatory tailwind in immunology: the EMA issued a positive opinion on Olumiant for alopecia, which could broaden Lilly’s immunology footprint and diversify revenue streams outside metabolic drugs. Yahoo Finance: EMA Olumiant opinion
• Neutral Sentiment: Lilly continues M&A/partnering activity (Ventyx Biosciences merger approval), which adds R&D assets but is incremental to the core GLP‑1/peptide franchise; monitor integration and milestones. TipRanks: Ventyx merger approval
• Negative Sentiment: Investor concerns on pricing, competition and a recent pullback: analysts and commentary note a month‑long decline amid fears of pricing pressure, insurer/employer cost controls, and rival weight‑loss entrants — factors that can compress near‑term growth expectations and valuations. Zacks: pricing fears and competition

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LLY. Guggenheim boosted their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Daiwa Securities Group boosted their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Argus lifted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, National Bank Financial set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Stock Performance

The company has a market cap of $927.18 billion, a PE ratio of 42.83, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40. The firm’s fifty day moving average is $1,049.25 and its 200 day moving average is $936.91. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% compared to the same quarter last year. During the same period last year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Institutional Trading of Eli Lilly and Company

Several large investors have recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $30,000. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Finally, Dorato Capital Management acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.